Mark Voskoboynik

1.4k total citations · 1 hit paper
76 papers, 678 citations indexed

About

Mark Voskoboynik is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mark Voskoboynik has authored 76 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Mark Voskoboynik's work include Cancer Immunotherapy and Biomarkers (37 papers), CAR-T cell therapy research (18 papers) and Lung Cancer Treatments and Mutations (9 papers). Mark Voskoboynik is often cited by papers focused on Cancer Immunotherapy and Biomarkers (37 papers), CAR-T cell therapy research (18 papers) and Lung Cancer Treatments and Mutations (9 papers). Mark Voskoboynik collaborates with scholars based in Australia, United States and China. Mark Voskoboynik's co-authors include Elliot Chartash, Jane Healy, Adnan Nagrial, Kathryn F. Mileham, Antonio Jimeno, Todd M. Bauer, Corinne Maurice‐Dror, Jiaxin Niu, Hyun Cheol Chung and Vincent Chung and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Mark Voskoboynik

70 papers receiving 674 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

2021 196 citations Adnan Nagrial, Mark Voskoboynik et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Voskoboynik Australia	15	504	233	181	165	53	76	678
Fareeda Hosein United States	4	472 0.9×	190 0.8×	119 0.7×	146 0.9×	53 1.0×	8	581
Gataree Ngarmchamnanrith United States	14	379 0.8×	222 1.0×	232 1.3×	229 1.4×	62 1.2×	26	651
Christian Britschgi Switzerland	17	413 0.8×	145 0.6×	272 1.5×	289 1.8×	101 1.9×	59	770
Virginia Picasso Italy	12	400 0.8×	197 0.8×	314 1.7×	101 0.6×	56 1.1×	16	661
Rita Ruijter Netherlands	11	332 0.7×	422 1.8×	212 1.2×	92 0.6×	53 1.0×	14	841
Brian Belmontes United States	13	421 0.8×	169 0.7×	322 1.8×	203 1.2×	84 1.6×	22	757
Tijl Vermassen Belgium	14	285 0.6×	157 0.7×	183 1.0×	142 0.9×	59 1.1×	36	543
Antonio Cusmai Italy	11	292 0.6×	138 0.6×	197 1.1×	124 0.8×	109 2.1×	28	577
Gen Lin China	12	309 0.6×	120 0.5×	163 0.9×	251 1.5×	127 2.4×	64	537
Luis Paz Ares Spain	7	462 0.9×	154 0.7×	188 1.0×	262 1.6×	99 1.9×	10	665

Countries citing papers authored by Mark Voskoboynik

Since Specialization

Citations

This map shows the geographic impact of Mark Voskoboynik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Voskoboynik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Voskoboynik more than expected).

Fields of papers citing papers by Mark Voskoboynik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Voskoboynik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Voskoboynik. The network helps show where Mark Voskoboynik may publish in the future.

Co-authorship network of co-authors of Mark Voskoboynik

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Voskoboynik. A scholar is included among the top collaborators of Mark Voskoboynik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Voskoboynik. Mark Voskoboynik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Jayesh, Sanjeev Deva, Bo Gao, et al.. (2025). A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results. Cancer Chemotherapy and Pharmacology. 95(1). 99–99.

Davar, Diwakar, Ludimila Cavalcante, Nehal J. Lakhani, et al.. (2024). Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). Journal for ImmunoTherapy of Cancer. 12(8). e009474–e009474. 3 indexed citations

Azad, Arun, Craig Underhill, Howard Gurney, et al.. (2024). Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(16_suppl). 5058–5058. 1 indexed citations

Coward, Jermaine, Ganessan Kichenadasse, John Park, et al.. (2024). Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15010–e15010.

Tran, Ben, Mark Voskoboynik, Johanna C. Bendell, et al.. (2024). A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy. 16(11). 759–774. 5 indexed citations

Gao, Bo, Mark Voskoboynik, Adam Cooper, et al.. (2023). A phase 1 dose‐escalation study of the poly(ADP‐ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors. Cancer. 129(7). 1041–1050. 5 indexed citations

Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055. 15 indexed citations

Desai, Jayesh, Peter C.C. Fong, Víctor Moreno, et al.. (2023). A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. British Journal of Cancer. 128(8). 1418–1428. 10 indexed citations

Woollett, Anne, Mark Voskoboynik, Mark Shackleton, et al.. (2023). A capability framework to inform the fundamental requirements for clinical trial unit development, growth and long term success in outer metropolitan and rural areas. Contemporary Clinical Trials Communications. 32. 101072–101072. 1 indexed citations

10.

Parakh, Sagun, Steven Kao, Craig Lewis, et al.. (2021). Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology. 5(5). 561–568. 4 indexed citations

11.

Coward, Jermaine, Bo Gao, Mark Voskoboynik, et al.. (2021). 153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC). Annals of Oncology. 32. S1446–S1447. 2 indexed citations

12.

Lickliter, Jason D., Hui Gan, Mark Voskoboynik, et al.. (2020). <p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. Drug Design Development and Therapy. Volume 14. 1177–1189. 26 indexed citations

13.

Geva, Ravit, Mark Voskoboynik, Konstantin Dobrenkov, et al.. (2020). First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer. 126(22). 4926–4935. 47 indexed citations

14.

Souza, Paul de, Bo Gao, Mark Voskoboynik, et al.. (2020). 574P Updated results of phase I study of senaparib (IMP4297) in Australian patients with advanced solid tumours. Annals of Oncology. 31. S490–S490. 3 indexed citations

15.

Fong, Peter C.C., Víctor Moreno, Sophia Frentzas, et al.. (2020). 535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma. Annals of Oncology. 31. S468–S469. 1 indexed citations

16.

Voskoboynik, Mark, Linda Mileshkin, Hui Gan, et al.. (2019). Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results. Annals of Oncology. 30. v167–v167. 2 indexed citations

17.

Desai, Jayesh, Mark Voskoboynik, Ben Markman, et al.. (2018). Phase 1/2 study investigating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of anti-PD-L1 monoclonal antibody bgb-A333 alone and in combination with anti-PD-1 monoclonal antibody tislelizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS3113–TPS3113. 3 indexed citations

18.

Blackley, Elizabeth F., et al.. (2017). Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma. Annals of Oncology. 28. v440–v440. 2 indexed citations

19.

Moschetta, Michele, Benjamin Kasenda, Gabriel Mak, et al.. (2016). Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition. Annals of Oncology. 27. vi24–vi24. 2 indexed citations

20.

Dean, Emma, Nicola Steele, Hendrik‐Tobias Arkenau, et al.. (2016). SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Annals of Oncology. 27. vi439–vi439. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact